甲状腺乳头状癌中的BRAF突变
BRAF mutation in papillary thyroid carcinoma.
作者信息
Li Xinying, Abdel-Mageed Asim B, Kandil Emad
机构信息
Department of Surgery, Tulane University, School of medicine New Orleans, LA, USA.
出版信息
Int J Clin Exp Med. 2012;5(4):310-5. Epub 2012 Aug 22.
Abstract
BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC). Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of the BRAF mutation alternation in PTC. Detection of BRAF mutation on FNA specimen before surgery is recommended as a useful diagnostic marker and prognostic indicator for PTC, and thus influences surgeon's decision on management of PTC. Recent studies have focused on inhibition of BRAF activation and several small molecules have been developed as targeting therapy.
摘要
BRAF突变是甲状腺癌中最常见的基因改变，尤其是在乳头状甲状腺癌（PTC）中。BRAF突变导致的BRAF/MAPK信号通路过度激活在PTC的肿瘤发生和发展中起核心作用。BRAF突变与PTC不良临床病理特征的关联进一步证明了BRAF突变改变在PTC中的重要性。建议在手术前对FNA标本进行BRAF突变检测，作为PTC的有用诊断标志物和预后指标，从而影响外科医生对PTC的治疗决策。最近的研究集中在抑制BRAF激活，并且已经开发了几种小分子作为靶向治疗药物。
相似文献
1
BRAF mutation in papillary thyroid carcinoma.甲状腺乳头状癌中的BRAF突变
Int J Clin Exp Med. 2012;5(4):310-5. Epub 2012 Aug 22.
2
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.甲状腺乳头状癌中的BRAF突变：致病作用、分子基础及临床意义。
Endocr Rev. 2007 Dec;28(7):742-62. doi: 10.1210/er.2007-0007. Epub 2007 Oct 16.
3
Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.BRAF基因突变状态、甲状腺乳头状癌原发肿瘤的临床病理特征与淋巴结转移之间的相关性。
Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624. Epub 2014 May 16.
4
The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.BRAF（V600E）突变作为甲状腺内乳头状甲状腺癌患者预后不良因素的作用。
Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008. Epub 2014 Mar 18.
5
The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.BRAF V600E突变作为甲状腺乳头状癌预后分层潜在标志物的作用：一项长期随访研究
Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.
6
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.甲状腺乳头癌中的 BRAF 突变：致病作用及临床意义。
J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3.
7
Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.应用液滴数字 PCR 检测甲状腺乳头状癌细针抽吸液中的 BRAF V600E 突变。
Clin Chim Acta. 2019 Apr;491:91-96. doi: 10.1016/j.cca.2019.01.017. Epub 2019 Jan 22.
8
BRAF mutations in papillary thyroid carcinoma.甲状腺乳头状癌中的BRAF突变
Endocr Regul. 2006 Dec;40(4):129-38.
9
Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.BRAF V600E突变在传统型乳头状甲状腺癌甲状腺切除范围及淋巴结清扫中的作用
Surgery. 2015 Dec;158(6):1500-11. doi: 10.1016/j.surg.2015.05.016. Epub 2015 Jun 26.
10
Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.甲状腺病理学中 BRAF 突变检测的临床影响：作为诊断、预后和治疗应用的潜在用途。
Curr Med Chem. 2010;17(17):1839-50. doi: 10.2174/092986710791111189.
引用本文的文献
1
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.甲状腺癌：流行病学、分类、危险因素、诊断和预后标志物以及当前的治疗策略。
Int J Mol Sci. 2025 May 28;26(11):5173. doi: 10.3390/ijms26115173.
2
Exploring the versatility of miRNA-128: a comprehensive review on its role as a biomarker and therapeutic target in clinical pathways.探索 miRNA-128 的多功能性：miRNA-128 作为生物标志物和治疗靶点在临床途径中的作用的综合综述。
Mol Biol Rep. 2024 Jul 28;51(1):860. doi: 10.1007/s11033-024-09822-w.
3
Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma.一名患有BRAF V600E+乳头状甲状腺癌患者的骶骨转移。
J Surg Case Rep. 2023 Nov 10;2023(11):rjad585. doi: 10.1093/jscr/rjad585. eCollection 2023 Nov.
4
Transcriptomic Analysis Reveals Dysregulation of the Mycobiome and Archaeome and Distinct Oncogenic Characteristics according to Subtype and Gender in Papillary Thyroid Carcinoma.转录组分析揭示了根据甲状腺乳头状癌的亚型和性别失调的真菌组和古菌组以及独特的致癌特征。
Int J Mol Sci. 2023 Feb 5;24(4):3148. doi: 10.3390/ijms24043148.
5
The Emerging Role of m6A Modification in Endocrine Cancer.m6A修饰在内分泌癌中的新兴作用
Cancers (Basel). 2023 Feb 6;15(4):1033. doi: 10.3390/cancers15041033.
6
Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant.具有高细胞特征的经典乳头状甲状腺癌与高细胞变异型的临床病理特征及肿瘤学结局比较。
Gland Surg. 2022 Jan;11(1):56-66. doi: 10.21037/gs-21-678.
7
RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype.RET融合阳性的乳头状甲状腺癌与更具侵袭性的表型相关。
Ann Surg Oncol. 2022 Mar 1. doi: 10.1245/s10434-022-11418-2.
8
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib.Wnt/β-catenin 激活上调 BRAF 甲状腺乳头状癌细胞中的 TRIB2，从而赋予 BRAF 抑制剂 vemurafenib 耐药性。
Cancer Chemother Pharmacol. 2021 Jul;88(1):155-164. doi: 10.1007/s00280-021-04270-w. Epub 2021 Apr 16.
9
Prediction of driver variants in the cancer genome via machine learning methodologies.通过机器学习方法预测癌症基因组中的驱动变异。
Brief Bioinform. 2021 Jul 20;22(4). doi: 10.1093/bib/bbaa250.
10
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.蛋白酪氨酸磷酸酶受体C型的上调与桥本甲状腺炎和乳头状甲状腺癌的联合相关，并预示预后不良。
Onco Targets Ther. 2019 Oct 14;12:8479-8489. doi: 10.2147/OTT.S226426. eCollection 2019.
本文引用的文献
1
BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.BRAF V600E 突变并不预测 TNM Ⅰ或Ⅱ期甲状腺乳头状癌患者长期随访后的复发。
APMIS. 2012 May;120(5):380-6. doi: 10.1111/j.1600-0463.2011.02844.x. Epub 2011 Nov 25.
2
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.BRAF V600E 突变与甲状腺乳头状癌的肿瘤侵袭性相关。
World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.
3
The molecular diagnosis and management of thyroid neoplasms.甲状腺肿瘤的分子诊断与处理。
Curr Opin Oncol. 2012 Jan;24(1):35-41. doi: 10.1097/CCO.0b013e32834dcfca.
4
BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.BRAFV600E 突变、TIMP-1 上调和 NF-κB 激活：闭合甲状腺乳头癌三联征的循环。
Endocr Relat Cancer. 2011 Nov 14;18(6):669-85. doi: 10.1530/ERC-11-0076. Print 2011 Dec.
5
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.BRAF V600E 突变和年龄较大（≥65 岁）均与复发性甲状腺乳头状癌相关。
Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.
6
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.BRAF(V600E)与甲状腺癌的微环境：推动癌症进展的功能联系。
Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Epub 2011 Mar 29.
7
The utility of BRAF testing in the management of papillary thyroid cancer.BRAF 检测在甲状腺乳头状癌管理中的应用。
Oncologist. 2010;15(12):1285-93. doi: 10.1634/theoncologist.2010-0156. Epub 2010 Dec 8.
8
BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.BRAF(V600E) 突变与甲状腺乳头状癌患者发生需要再次手术的淋巴结复发风险增加相关。
Surgery. 2010 Dec;148(6):1139-45; discussion 1145-6. doi: 10.1016/j.surg.2010.09.005.
9
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.PLX-4032，一种用于潜在治疗恶性黑色素瘤的小分子B-Raf抑制剂。
Curr Opin Investig Drugs. 2010 Jun;11(6):699-706.
10
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.甲状腺乳头癌中的 BRAF 突变：致病作用及临床意义。
J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3.
Zotero 插件